ArticleNature communications2026
Enzymatic colorimetric encoding-based digital medicine for pancreatic cancer diagnosis.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Digital medicine leverages digital biomarkers by algebraically integrating multiple biomarkers to reflect disease status. Colorimetric analysis offers an intuitive readout, but colorimetric-based digital medicine remains underexplored. Here we show an Enzymatic Colorimetric Encoding-based Digital Medicine platform (EnCODE). By harnessing enzyme-catalyzed multicolor encoding in tandem with the programmability of DNA technology, EnCODE converts multidimensional miRNA information into recognizable optical signals. We demonstrate that these signals are decodable and can be interpreted by visual inspection or spectral analysis, facilitating dimensionality reduction and visualization of disease states. Additionally, EnCODE integrates a continuous weighting mechanism that enables accurate mapping of digital biomarkers. In a cohort of 163 pancreatic cancer clinical samples, EnCODE achieves 96% detection sensitivity and 90% overall accuracy-comparable to the 96% sensitivity and 91% overall accuracy with conventional molecular diagnostic methods. We increase data density through three-dimensional color encoding and hyperspectral imaging-based analysis, enabling an intuitive color-coded molecular readout.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.